Abstract
Injectable estrogens are options for gender-affirming hormone therapy per guidelines, which suggest intramuscular dosages of 5-30 mg every 2 weeks or 2-10 mg weekly with estradiol cypionate or valerate interchangeably. Data among transgender and gender-diverse patients are limited due to local unavailability and concerns around laboratory assay variability and estradiol (E2) level fluctuation. We note a concerning trend where patients are prescribed high-dose injections based on the guidelines leading to serum E2 levels well above the range recommended in the same guidelines. Our review indicates that 5 mg weekly or lower should be prescribed when initiating injectable estrogens to avoid supraphysiologic E2 levels.
| Original language | English |
|---|---|
| Pages (from-to) | 463-465 |
| Number of pages | 3 |
| Journal | Transgender Health |
| Volume | 9 |
| Issue number | 6 |
| DOIs | |
| State | Published - 1 Dec 2024 |
Keywords
- estradiol cypionate
- estradiol level
- estradiol valerate
- gender-affirming hormone therapy
- injectable estrogen dosing
- transgender
Fingerprint
Dive into the research topics of 'Revisiting Injectable Estrogen Dosing Recommendations for Gender-Affirming Hormone Therapy'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver